Dova Pharmaceuticals is declining to comment on the outcome of its request for its lead compound, avatrombopag, to be fast-tracked when the company files for approval across the EU.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) considered Dova’s request for accelerated assessment at its...








